This single-arm pilot study tries to invesitgate how well giving icotinib with rh-endostatin (Endostar®) works in treating patients with advanced stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations. Icotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Anti-angiogeneiss drug, such as rh-endostatin, can block tumor growth by inhibiting the ability of tumors to grow new blood vessels and spread. It is not yet known whether icotinib is more effective when given with rh-endostatin in NSCLC patients with EGFR activating mutations.
Name: Endostar and icotinib
Description: Endostar and icotinib are used as combination therapy.Type: DrugEndostar and icotinib
Description: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Measure: Safety: Number of Participants with Adverse Events Time: 12 monthsSingle Group Assignment
There is one SNP
Inclusion Criteria: - Histologic documentation of non small cell lung cancer, with activating epidermal growth factor receptor (defined as deletion 19 or exon 21 L858R mutation). --- L858R ---
- Other active malignancy Inclusion Criteria: - Histologic documentation of non small cell lung cancer, with activating epidermal growth factor receptor (defined as deletion 19 or exon 21 L858R mutation). --- L858R ---
EGFR mutation status: activating mutation (defined as deletion 19 or exon 21 L858R mutation). --- L858R ---